Pharmacokinetics of Dasatinib
Jana Hořínková1, Martin Šíma2, Ondřej Slanař2
1Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. jana.horinkova@lf1.cuni.cz.
Prague Medical Report
|October 7, 2019
Summary
Dasatinib is a key drug for chronic myeloid leukaemia (CML) treatment, effective even with resistance. Its absorption is sensitive to gastric pH and drug interactions, impacting patient exposure.
Area of Science:
- Pharmacology
- Oncology
- Hematology
Background:
- Tyrosine kinase inhibitors (TKIs) are crucial for managing chronic myeloid leukemia (CML).
- Dasatinib is a TKI targeting Bcr-Abl and Src, showing efficacy in resistant CML cases.
- Understanding dasatinib's pharmacokinetics is vital for optimizing patient treatment and exposure.
Purpose of the Study:
- To summarize the key pharmacokinetic properties of dasatinib.
- To highlight factors influencing dasatinib absorption and exposure.
- To identify potential drug interactions affecting dasatinib efficacy.
Main Methods:
- Literature review of dasatinib pharmacokinetics.
- Analysis of factors affecting drug absorption, distribution, metabolism, and excretion.
- Identification of drug-drug interactions and food-drug interactions.
Main Results:
- Dasatinib absorption is significantly affected by gastric pH.
- Co-administration with drugs affecting cytochrome P450 can lead to interactions.
- Specific pharmacokinetic characteristics are essential for achieving adequate patient exposure.
Conclusions:
- Dasatinib's pharmacokinetic profile requires careful consideration for effective CML management.
- Gastric pH modulation and drug interactions are critical factors to monitor.
- Optimizing dasatinib exposure through pharmacokinetic understanding improves treatment outcomes in CML.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
188
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
188
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
165
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
165
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
231
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
231
01:10Pharmacokinetics: Overview
8.6K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
8.6K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
179
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
179